The 5 Unspoken Rules of Building a Defensible AI Moat in Biotech
Most founders in biotech AI are chasing a ghost. They think a better model, a few percentage points of accuracy, is their golden ticket. They’re wrong. I’ve seen it dozens of times from the investor side of the table, and I’ve lived it as a founder. Building a real, defensible moat in this space has almost nothing to do with the elegance of your algorithm and everything to do with the ugly, unglamorous plumbing you build around it.
I remember sitting in a pitch meeting a few years back. A team of brilliant PhDs from Stanford, truly top-tier talent. They had a novel neural network architecture for analyzing radiology scans. It was, on paper, 5% more accurate than the leading solutions. They thought they had a unicorn. I passed. Why? Because they couldn’t answer the one question that mattered: “How do you get this into a hospital?”
That’s the uncomfortable truth. In the brutal, regulated, and deeply entrenched world of healthcare, your model is just the beginning. It’s the ticket to the game, not the win itself. Here are the five unspoken rules I’ve learned—often the hard way—about what it really takes.
1. The Data Isn’t the Moat. The Workflow Is.
Everyone parrots the line “data is the new oil.” It’s a tired cliché, and in healthcare, it’s a dangerous oversimplification. Yes, you need high-quality, proprietary data. But that’s table stakes. The real defensibility comes from embedding your AI so deeply into a clinical workflow that ripping it out would be like performing open-heart surgery on the hospital’s IT system.
Think about it from a radiologist’s perspective. They’re already overworked, staring at a dozen different screens, and battling burnout. The last thing they want is another standalone application to log into. Your tool can’t be a detour. It has to become part of the highway. It needs to integrate seamlessly with the Picture Archiving and Communication System (PACS), the Electronic Health Record (EHR), and the reporting software. The AI’s output should appear as a native data layer, an intuitive insight within the exact same screen they already use for 99% of their work.
When we were building out a tool for automated diagnostic imaging analysis, we spent the first six months not on the model, but on the integration points. We built custom middleware that could talk to systems from GE, Siemens, and Philips. It was a nightmare of legacy protocols and terrible documentation. But it was the single best investment we made. Once we were in, we were in. The hospital’s own IT team became our biggest defenders because our system made their lives easier.
2. Your “Customer” is a Committee of Skeptics
In a typical SaaS sale, you’re trying to convince one person, maybe two. The economic buyer and the user. In healthcare, you’re selling to a small army. You have the clinician (the user), the department head (the champion), the hospital administrator (the economic buyer), the IT department (the gatekeeper), legal and compliance (the risk-averse), and the reimbursement specialist (the one who actually figures out how you get paid). Each of them has a different set of priorities and a different reason to say “no.”
I’ve seen more promising biotech AI startups die in the labyrinth of hospital procurement than from any technical failure. You need a strategy for each of these stakeholders. For the clinician, it’s about saving time and reducing errors. For the administrator, it’s a clear ROI story—how your tool reduces patient stay duration or avoids costly readmissions. For IT, it’s about security, HIPAA compliance, and not breaking their existing infrastructure. You have to speak all of these languages fluently.
One of my angel investments, a company in the mental health space, cracked this code brilliantly. Their AI-powered tool helped therapists track patient progress between sessions. Instead of selling it as a “better therapy” tool, they framed it as a “better documentation” tool. It automated the tedious note-taking process for therapists (a huge win for them) while providing the clinic with structured data for billing and outcomes tracking (a huge win for the administrators). They solved two problems in one, and the sale became a no-brainer.
3. The “Black Box” Will Kill You
Trust is the currency of medicine. For centuries, the entire system has been built on a foundation of explainable, evidence-based decisions. Then we come along with our deep learning models and say, “Just trust the algorithm.” It’s a non-starter.
Explainability isn’t a nice-to-have feature in healthcare AI; it’s a core requirement. A doctor will not, and should not, alter a patient’s treatment plan based on an AI’s recommendation without understanding why the AI made that recommendation. They need to see the receipts. What features in the image did the model look at? What patient data points were most influential? Can you show the range of normal and flag the specific anomaly?
This is where a lot of pure-play AI teams stumble. They’re so focused on predictive accuracy that they neglect interpretability. The best biotech AI companies are the ones that treat the user interface for explainability with as much importance as the model itself. They build visualizations that highlight the AI’s reasoning, making it a collaborative tool for the clinician, not a replacement.
Look at what’s happening in AI-assisted drug discovery. The models that are gaining traction aren’t just spitting out a list of potential compounds. They’re showing the specific protein-folding simulations, the binding affinity scores, and the potential off-target effects. They’re giving the chemists the building blocks to make an informed decision.
4. Regulation is Not an Obstacle. It’s a Moat.
Most founders see the FDA and other regulatory bodies as a giant, expensive roadblock. They complain about the paperwork, the clinical trials, the endless hoops to jump through. This is a loser’s mentality. The smart founders see regulation for what it is: a massive, government-enforced barrier to entry.
Getting FDA clearance for a Software as a Medical Device (SaMD) is a brutal, multi-year, multi-million dollar process. But the moment you get that clearance, you’ve built a moat that is incredibly difficult for competitors to cross. You’ve proven your tool is safe and effective according to the highest standards in the world. It’s a stamp of approval that instantly builds trust with every stakeholder in the hospital.
Your competitors who are trying to sell a “wellness” app or a “research-use-only” tool are now playing in a completely different league. They can’t make clinical claims. They can’t be used for diagnosis. They’re stuck in the minor leagues while you’re playing in the World Series.
My advice to every biotech AI founder is to hire a regulatory expert on day one. Don’t treat it as an afterthought. Design your entire product development lifecycle, your quality management system, and your data collection practices with regulatory approval as the end goal. It’s painful, but it’s how you build a company that lasts.
5. The Business Model is the Most Important Innovation
We’ve saved the most important rule for last. You can have the best model, the deepest workflow integration, the happiest customers, and full FDA clearance, but if you don’t have a way to get paid, you’re a non-profit. Reimbursement is the final boss in healthcare AI.
How does the hospital actually make money by using your tool? Is there an existing CPT code they can bill against? Do you need to apply for a new one? Can you structure your sale as a subscription that aligns with their existing budget cycles? Or do you go for a risk-sharing model where you only get paid if you deliver a specific, measurable outcome?
This is where so many companies fail. They build a phenomenal product that saves lives but doesn’t fit into the arcane, convoluted financial plumbing of the US healthcare system. The companies that win are the ones that innovate on the business model as much as they do on the technology.
One of the most successful AI radiology companies I’ve seen didn’t charge per scan. They charged a small fee for every negative scan the AI confidently ruled out. This was genius. It aligned their incentives perfectly with the hospital’s. The hospital saved a huge amount of money by not having to pay an expensive radiologist to review thousands of normal scans, and the AI company got a cut of the savings. It was a win-win.
Building a defensible company in biotech AI is a game of inches, played over years. It’s not about one big breakthrough. It’s about the patient, methodical work of laying bricks. It’s about understanding that the algorithm is just one brick in a very large wall. The real moat is the wall itself—the integrations, the stakeholder alignment, the trust, the regulatory clearance, and the business model. That’s the unspoken truth, and it’s the only thing that will protect you when the AI hype cycle inevitably turns.
Conclusion: The Real Work Begins After the Model is Built
So, if you're a founder in this space, I urge you to look beyond the model. The algorithm is the easy part. The hard part—the real work—is everything else. It's the messy, complicated, and deeply human challenge of integrating a new way of thinking into a system that is fundamentally resistant to change. But for those who are willing to do the hard work, the opportunity is immense. You won't just be building a company; you'll be changing the future of medicine. And that's a legacy worth fighting for.
Frequently Asked Questions
What's the most common pushback you get on this?
People often push back by citing exceptions or edge cases. And they're usually right that exceptions exist. But building a strategy around exceptions rather than patterns is a losing game for most founders.
How has this view evolved over time?
My thinking on most topics has changed significantly over the years. Early in my career, I held many conventional views that experience proved wrong. I try to update my beliefs when the evidence changes.
Do all experts agree with this view?
No, and that's fine. The best ideas in business are often contrarian. I share my perspective based on my experience and data, but I encourage you to seek out opposing viewpoints and form your own conclusions.